ArticleFrontiers in oncology2021
Molecular Identification and Genetic Characterization of Early-Stage Multiple Primary Lung Cancer by Large-Panel Next-Generation Sequencing Analysis.
Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 27 citations in OpenAlex.
- Next-Generation Sequencing vs. Clinical-Pathological Assessment in Diagnosis of Multiple Lung Cancers: A Systematic Review and Meta-Analysis.Thoracic cancer · 2025Pooled it
- Differential Diagnostic Value of Histology in MPLC and IPM: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2022Pooled it
- Article
- A CT-based deep learning approach to differentiate multiple primary lung cancers, metastases, and benign nodules.BMC cancer · 2026Article
- Article
- Multiple ground-glass nodules after lobectomy for multiple primary lung cancer: a case report.Frontiers in surgery · 2026Article
- Next-generation sequencing in early-stage multiple primary lung cancer: The prognostic significance of genomic accumulation status and BCL2L11Translational oncology · 2025Article
- CXCL1 and CXCL8: Reliable and feasible biomarkers differentiating intrapulmonary metastasis from multiple primary neoplasms in non-small cell lung cancers.Cancer biomarkers : section A of Disease markers · 2025Article
- [Molecular pathology of lung adenocarcinomas, EGFR T790M resistance mutation study].Magyar onkologia · 2024Article
- The pathogenic germline ETV4 P433L mutation identified in multiple primary lung cancer affect tumor stem-like property by Wnt/β-catenin pathway.Cell death & disease · 2024Article
- Super multiple primary lung cancers harbor high-frequency BRAF and low-frequency EGFR mutations in the MAPK pathway.NPJ precision oncology · 2024Article
- Genome Sequencing of Multiple Primary Lung Cancers Harbouring Mixed Histology and Spontaneously Regressing Small-Cell Lung Cancer.Journal of personalized medicine · 2024Article
- Diagnosis and management of multiple primary lung cancer.Frontiers in oncology · 2024Review
- Classification of multiple primary lung cancer in patients with multifocal lung cancer: assessment of a machine learning approach using multidimensional genomic data.Frontiers in oncology · 2024Article
- Using molecular characteristics to distinguish multiple primary lung cancers and intrapulmonary metastases.PeerJ · 2024Article
- Genetic trajectory and clonal evolution of multiple primary lung cancer with lymph node metastasis.Cancer gene therapy · 2023Article
- Lineage tracing for multiple lung cancer by spatiotemporal heterogeneity using a multi-omics analysis method integrating genomic, transcriptomic, and immune-related features.Frontiers in oncology · 2023Article
- Review
- Clinicopathologic Characteristics and Outcomes of Simultaneous Multiple Primary Lung Cancer.Journal of oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe incidence of early stage multiple primary lung cancer (MPLC) has been increasing in recent years, while the ideal strategy for its diagnosis and treatment remains controversial. The present study conducted genomic analysis to identify a new molecular classification method for accurately predicting the diagnosis and therapy for patients with early stage MPLC.
methodsA total of 240 tissue samples from 203 patients with multiple-non-small-cell lung cancers (NSCLCs) (n = 30), early stage single-NSCLC (Group A, n = 94), and advanced-stage NSCLC (Group B, n = 79) were subjected to targeted multigene panel sequencing.
resultsThirty patients for whom next-generation sequencing was performed on >1 tumor were identified, yielding 45 tumor pairs. The frequencies of
conclusionsComprehensive molecular evaluation allows the unambiguous delineation of clonal relationships among tumors. In comparison, the Martini and Melamed criteria have notable limitations in the recognition of IM. Our results support the adoption of a large panel to supplement histology for strongly discriminating NSCLC clonal relationships in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.